[SCHEDULE 13G/A] Enbridge, Inc SEC Filing
- None.
- None.
Insights
TL;DR: Revenue up on M&A, but earnings, margins and cash flow deteriorated; leverage now elevated—overall negative.
The 9% sales lift is acquisition-led; organic demand is lacklustre, particularly at CPI. Gross and operating margins compressed materially as SAT integration costs, amortisation and inflation offset pricing. EPS fell 40% and cash generation weakened, raising concerns about the sustainability of dividend growth and buybacks. Net leverage (≈2.8× EBITDA pro forma) rises after drawing £300 m of term debt; higher rates magnify interest costs. Without faster synergy capture or CPI volume recovery, valuation multiples could compress. I rate the quarter negative.
TL;DR: Strategic logic of DLR/OpSec solid, but integration drag will persist through 2025; payoff hinges on synergy execution.
DLR expands SAT’s portfolio and geographic reach; paying ~2.1× 2024 sales is sensible if projected synergies materialise. Non-controlling interest structure in Ghana adds complexity but offers emerging-market upside. Management expects $10-15 m of one-time integration cost—modest relative to deal size. However, immediate EPS dilution and debt load highlight execution risk. If SAT realises cross-selling potential and CPI stabilises, CXT could regain double-digit EPS growth from 2026. Near-term view is neutral-to-cautiously positive.